PADI2 and glioblastoma: We have previously shown that both pan-PAD inhibitor Cl-amidine and PAD2, 3, and 4 isozyme-specific inhibitors modulate a range of pro- and anti-oncogenic miRs in cancers such as glioblastoma multiforme (GBM), as well as in cancer cell-derived EVs, including miR-21 and miR-126 [15,17].